


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T14:05:12Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406374" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406374</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>bmcneul</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Neurol</journal-id><journal-id journal-id-type="iso-abbrev">BMC Neurol</journal-id><journal-id journal-id-type="pmc-domain-id">48</journal-id><journal-id journal-id-type="pmc-domain">bmcneul</journal-id><journal-title-group><journal-title>BMC Neurology</journal-title></journal-title-group><issn pub-type="epub">1471-2377</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406374</article-id><article-id pub-id-type="pmcid-ver">PMC12406374.1</article-id><article-id pub-id-type="pmcaid">12406374</article-id><article-id pub-id-type="pmcaiid">12406374</article-id><article-id pub-id-type="pmid">40898083</article-id><article-id pub-id-type="doi">10.1186/s12883-025-04406-y</article-id><article-id pub-id-type="publisher-id">4406</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>ETRAISI registry report: clinical characteristics and related factors of outcome in reperfusion-eligible AIS patients</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Ghabaee</surname><given-names initials="M">Mojdeh</given-names></name><address><email>mojdeh.ghabaee@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Eskandarieh</surname><given-names initials="S">Sharareh</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Izadi</surname><given-names initials="N">Neda</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hosseini</surname><given-names initials="S">Siavash</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kiani</surname><given-names initials="I">Iman</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Jameie</surname><given-names initials="M">Melika</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Azizan</surname><given-names initials="Z">Zahra</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mojahed</surname><given-names initials="N">Nahid</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01c4pz451</institution-id><institution-id institution-id-type="GRID">grid.411705.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 0166 0922</institution-id><institution>Iranian Center of Neurological Research, Neuroscience Institute, </institution><institution>Tehran University of Medical Sciences, </institution></institution-wrap>Tehran, Iran </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01c4pz451</institution-id><institution-id institution-id-type="GRID">grid.411705.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 0166 0922</institution-id><institution>Multiple Sclerosis Research Center, Neuroscience Institute, </institution><institution>Tehran University of Medical Sciences, </institution></institution-wrap>Tehran, Iran </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/034m2b326</institution-id><institution-id institution-id-type="GRID">grid.411600.2</institution-id><institution>Research Center for Social Determinants of Health, Research Institute for Metabolic and Obesity Disorders, Research Institute for Endocrine Sciences, </institution><institution>Shahid Beheshti University of Medical Sciences, </institution></institution-wrap>Tehran, Iran </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01c4pz451</institution-id><institution-id institution-id-type="GRID">grid.411705.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 0166 0922</institution-id><institution>Students&#8217; Scientific Research Center, </institution><institution>Tehran University of Medical Sciences, </institution></institution-wrap>Tehran, Iran </aff></contrib-group><pub-date pub-type="epub"><day>2</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>25</volume><issue-id pub-id-type="pmc-issue-id">478179</issue-id><elocation-id>374</elocation-id><history><date date-type="received"><day>11</day><month>7</month><year>2025</year></date><date date-type="accepted"><day>14</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>02</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="12883_2025_Article_4406.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Stroke remains a major cause of disability and mortality worldwide, requiring comprehensive data collection for better management strategies. The Endovascular Thrombolysis Registry in Acute Ischemic Stroke of Iran (ETRAISI) was established March 21, 2023, to systematically document stroke epidemiology, treatment approaches, and outcomes in Iran. This study presents an analysis of registry data, focusing on patient characteristics, treatment time scales, and functional outcomes.</p></sec><sec><title>Methods</title><p id="Par2">A total of 115 patients diagnosed with acute stroke were enrolled at ETRAISI between March 21, 2023, and March 19, 2024. Clinical and demographic data, including stroke subtype, risk factors, treatment modalities, and outcome measures, were collected. Treatment time scales, such as door-to-needle time (DTN) for thrombolysis and door-to-groin puncture time (DTP) for thrombectomy, were analyzed. Factors associated with National Institutes of Health Stroke Scale (NIHSS) at discharge were assessed using multiple linear regression.</p></sec><sec><title>Results</title><p id="Par3">Among 313 patients admitted at hospital as possible acute ischemic stroke (AIS), a total of 158 patients&#8217; candidate for intra-venous thrombolysis (IVT) or mechanical thrombectomy (MT) within 6-hours of onset, 115 enrolled, 81 patients (70.4%) underwent IVT, 8 (7.0%) patients received MT, and 26 patients (22.6%) underwent bridging therapy. The most common stroke risk factors were hypertension in 77 patients (67.0%), followed by diabetes in 39 (33.9%), and ischemic heart disease in 33 patients (28.7%). The median (IQR) of DTN was 65 (48-84.5) minutes, while the median (IQR) of DTP was 109 (75&#8211;158) minutes. The most frequent stroke etiology was undetermined observed in 33% patients. Multiple linear regression identified National Institutes of Health Stroke Scale (NIHSS) at admission, age, diastolic blood pressure, and treatment related complication were significantly associated with functional outcomes (<italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05).</p></sec><sec><title>Conclusion</title><p id="Par4">This study reported stroke management and outcomes in Iran. Identifying treatment time tracker and outcome related factors may inform policy changes and improve acute stroke care in Iran and Other developing countries. Benchmarking these findings against international registries can guide targeted interventions for optimizing stroke treatment.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Stroke</kwd><kwd>Stroke registry</kwd><kwd>Intra-venous thrombolysis</kwd><kwd>Mechanical thrombectomy</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">Stroke known as a global health issue, the second cause of death, and the third cause of disability-adjusted life years (DALYs) worldwide [<xref ref-type="bibr" rid="CR1">1</xref>]. Despite substantial advancements in prevention, acute management, and rehabilitation strategies, the burden of stroke is going to grow, particularly in low- and middle-income countries [<xref ref-type="bibr" rid="CR2">2</xref>]. The complexity of stroke as a disease&#8212;encompassing multiple subtypes, varied etiologies, and diverse clinical presentations&#8212;necessitates robust, real-world data to inform evidence-based practices, optimize care delivery, and improve outcomes [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par6">One major purpose of developing the registries is to recognize the persistent disparities in stroke care across regions and socioeconomic groups [<xref ref-type="bibr" rid="CR4">4</xref>]. Studies have shown that patients in low-middle income countries often receive delayed acute treatments (door-to-needle time&#8201;&gt;&#8201;60&#160;min), leading to poorer outcomes [<xref ref-type="bibr" rid="CR5">5</xref>]. Clinical trials provide high-quality data on healthcare challenges, disease trends, and treatment outcomes but often lack generalizability on broader populations [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par7">In Iran, the prenotification SAMA code&#8212;activated at 7 days and 24&#160;h&#8212;was established to improve the stroke care system. This system is designed to detect and facilitate care for patients suspected of having acute ischemic stroke by alerting healthcare providers, including neurologists, emergency medicine specialists, and technical staff, to prioritize these patients. By doing so, the initiation of decision-making and activation of the recall system can be appropriately expedited [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par8">In addition, stroke unit care has been established in designated stroke treatment hospitals. These units are equipped to hospitalize patients with continuous ECG and blood pressure monitoring. However, the lack of systematic evaluation of stroke care and identification of pitfalls in the current comprehensive stroke care system remains a challenge. Establishing a stroke registry and performing data analysis could provide valuable insights for improving stroke care delivery [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>].</p><p id="Par9">Registries address this gap by capturing real-world data, offering valuable insights into clinical challenges, and providing a precise research foundation for clinicians. Additionally, these registries show patient outcomes longitudinally, determine the predictors of functional recovery, stroke recurrence, and mortality, which are essential for improving secondary prevention strategies [<xref ref-type="bibr" rid="CR9">9</xref>]. Besides enhancing clinical care, the registry supports research and policymaking by informing public health politicians to reduce the stroke burden, such as community awareness campaigns, emergency service improvements, and resource optimization [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par10">Our study aimed to provide a comprehensive overview of the Endovascular Thrombolysis Registry in Acute Ischemic Stroke of Iran (ETRAISI), including its design, and key findings. We highlight the registry&#8217;s role in identifying gaps in stroke care, monitoring disease trends, and contributing to the growing body of knowledge on stroke management. By doing so, we aim to demonstrate the importance of stroke registries in improving patient outcomes and advancing the field of stroke research and promoting the health policy.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Study design and setting</title><p id="Par11">ETRAISI (<ext-link ext-link-type="uri" xlink:href="http://icnr.etraisi.ir">http://icnr.etraisi.ir</ext-link>) is a hospital- based registry, approved by Tehran University designed to collect detailed data from March 21, 2023, to March 19, 2024, on patients with acute ischemic stroke. This cohort study was conducted following the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines. The registry was established in 2023 to collect systemically all stroke patients&#8217; data at comprehensive stroke center of Imam complex hospital (Tehran provinces of Iran) and has been ongoing to track trends in stroke epidemiology, treatment, and outcomes.</p></sec><sec id="Sec4"><title>Patient eligibility and enrollment</title><p id="Par12">We included patients aged over 18 years presenting a confirmed diagnosis of ischemic stroke within 6&#160;h of symptom onset based on BEFAST (balance, eye, face, arm, speech, time) and candidates for thrombolysis or thrombectomy by a neurologist at a university-affiliated hospital according to AHA-2019 [<xref ref-type="bibr" rid="CR11">11</xref>]. Exclusion criteria included the presence of Intracranial hemorrhage (ICH), mild acute ischemic stroke (NIHSS&#8201;&lt;&#8201;4) and transient ischemic attacks (TIAs), and patients on anticoagulant therapy with INR&#8201;&gt;&#8201;1.7, and other criteria based on AHA2019 [<xref ref-type="bibr" rid="CR11">11</xref>].</p></sec><sec id="Sec5"><title>Data collection and variables</title><p id="Par13">Data collection was made through a standardized protocol, designed based on literature reviews, 2019 AHA guidelines, and established registry forms [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>], to ensure consistency and reliability. A trained neurologist, neurology resident, and a trained stroke unit care nurse -all certified in 2019 AHA guideline protocols- recorded the data using an electronic system and paper forms, which included:</p><p id="Par14">
<list list-type="order"><list-item><p id="Par15"><bold>Baseline Characteristics and Risk Factors</bold>: Age, sex, Comorbidities, and risk factors (e.g., hypertension, diabetes, smoking, dyslipidemia, atrial fibrillation, and prior stroke, OCP), vital signs, laboratory data, drug history.</p></list-item><list-item><p id="Par16"><bold>Stroke Characteristics</bold>: Stroke subtypes (Trial of Org 10172 in Acute Stroke Treatment: TOAST) based on the initial imaging (MRI/CT) findings, pattern of deficit (including Fluctuating, Immediately Complete, Progressive, Rapidly Resolved), and stroke severity measured by the NIHSS.</p></list-item><list-item><p id="Par17"><bold>Imaging Data</bold>: Infarct size assessed by non-contrast brain CT (ASPECT), presence of large vessel occlusion (CTA-confirmed occlusion of ICA, M1/M2 MCA, PCA, or basilar artery) [<xref ref-type="bibr" rid="CR14">14</xref>] and collateral circulation (Graded on multiphase CTA using modified ASITN/SIR scale) [<xref ref-type="bibr" rid="CR13">13</xref>].</p></list-item><list-item><p id="Par18"><bold>Acute Management</bold>: Treatments administered, including intravenous thrombolysis, mechanical thrombectomy after controlling SBP (&gt;&#8201;185), DBP (&gt;&#8201;105), and BS (&lt;&#8201;60 or &gt;&#8201;180).</p></list-item><list-item><p id="Par19"><bold>Timeline for AIS management</bold>: Symptom onset, door-to-needle time (DTN), and door-to-puncture time (DTP) were recorded. Delays were defined as DTN&#8201;&#8805;&#8201;60&#160;min or DTP&#8201;&#8805;&#8201;120&#160;min, and reasons for delays were documented.</p></list-item><list-item><p id="Par20"><bold>Stroke unit observation</bold>: all patients were evaluated for adverse effects of thrombolysis (angioedema, etc.,), blood pressure controls every 15&#160;min up to 24&#160;h. Follow up CT or MRI were done for excluding hyper perfusion syndrome [<xref ref-type="bibr" rid="CR15">15</xref>] and intra cerebral hemorrhage (PC1, PC2) [<xref ref-type="bibr" rid="CR16">16</xref>]. The anti-platelet started 24&#160;h after the intervention. Cardiac monitoring at stroke unit care and further evaluation such as echocardiography were done within 24&#160;h after intervention. Prophylaxis/treatment for DVT, delirium, aspiration pneumonia, bed sore, falling, and seizure performed as stroke unit protocol.</p></list-item><list-item><p id="Par21"><bold>Outcomes and Follow-Up</bold>: Functional status using the NIHSS at discharge and treatment related complications including cerebral edema, hemorrhagic transformation, remote ICH (classified per ECASS criteria) [<xref ref-type="bibr" rid="CR17">17</xref>], re-infarction, extracranial bleeding, and seizure [<xref ref-type="bibr" rid="CR18">18</xref>], were recorded.</p></list-item></list>
</p></sec><sec id="Sec6"><title>Ethical considerations</title><p id="Par22">The registry adheres to the ethical principles outlined in the Declaration of Helsinki. Ethical approval was obtained from the institutional review boards of all participating centers [IR.TUMS.MEDICINE.REC.1400.625]. Written informed consent was obtained from patients or their legal representatives prior to enrollment. For patients unable to provide consent due to the severity of their condition, consent was obtained from their legal tutor in accordance with local ethical guidelines.</p></sec><sec id="Sec7"><title>Statistical analysis</title><p id="Par23">Descriptive statistics were used to summarize baseline characteristics. The Kolmogorov&#8211;Smirnov test was applied to assess the normality of continuous variables. Normally distributed variables are presented as mean&#8201;&#177;&#8201;standard deviation, non-normally distributed variables as median and interquartile range (IQR), and categorical variables as frequencies (percentages). Factors associated with NIHSS were identified using simple and multiple linear regression (ENTER method). Variable selection was guided by literature review and specialist consensus, emphasizing variables with stronger theoretical relevance. Variables were initially screened via simple linear regression, retaining only those with statistical significance (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05) or those accounting for the largest patient proportion in the final model. As the NIHSS is a scale variable and was analyzed as a continuous outcome in multiple linear regression, B-coefficients were reported to indicate the magnitude and direction of the association. Analyses were performed using IBM SPSS 26, with statistical significance set at a two-tailed <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.05.</p></sec></sec><sec id="Sec8"><title>Results</title><p id="Par24">Among 313 patients admitted to hospital with possible acute ischemic stroke (AIS), 32(10.22%) were diagnosed with hemorrhagic stroke, 107 (34.18%) had stroke mimics, 16 (5.11%) had TIA, and 158 (50.47%) were diagnosed with AIS. Of 158 patients diagnosed with AIS, 20(6.38%) with mild acute ischemic stroke (NIHSS&#8201;&lt;&#8201;4), and 7 (2.23%) patients with abnormal coagulation state were excluded (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). A total of 115 AIS patients&#8217; candidates for thrombolysis/thrombectomy were included in the ETRAISI from March 21, 2023, to March 19, 2024. Of these eligible patients, 115 underwent thrombolysis, thrombectomy, or both; their data were reported and analyzed.<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Workflow algorithm. Flowchart of patient selection for ETRAISI registry: Out of 313 admitted patients with neurological deficits, 155 were excluded (32 hemorrhagic stroke, 16 TIA, 107 stroke mimics). Of the remaining, 115 were recorded in ETRAISI after excluding 43 patients for clinical reasons</p></caption><graphic id="MO1" position="float" orientation="portrait" xlink:href="12883_2025_4406_Fig1_HTML.jpg"/></fig></p><sec id="Sec9"><title>Clinical and baseline characteristics</title><p id="Par25">The mean (SD) of age was 68.71(14.75) years, and 62.6% (<italic toggle="yes">n</italic>&#8201;=&#8201;72) of the participants were male (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). Seventy-one Patients were transported by emergency medical services EMS (61.7%), 40 patients (34.8%) were transferred in Private, and 2 patients (3.5%) were in-hospital diagnosed with AIS. Both genders had almost the same transportation manner to hospital (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). Among the 115 patients eligible for therapy, 70.4% (<italic toggle="yes">n</italic>&#8201;=&#8201;81) were eligible for IVT, almost 7% for MT(<italic toggle="yes">n</italic>&#8201;=&#8201;8), and 22.6% received bridging therapy (<italic toggle="yes">n</italic>&#8201;=&#8201;26). The most common presenting symptom was hemiparesis, observed in 79.1% of patients (<italic toggle="yes">n</italic>&#8201;=&#8201;91). Other common symptoms included facial droop (57.4%), aphasia (37.4%), loss of consciousness (14.8%), and ataxia (7.8%) (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). The history of hypertension (HTN) was the most common comorbidity, affecting 77 (67.0%) patients. Diabetes mellitus (DM) was present in 39 (33.9%) patients, while ischemic heart disease (IHD) was noted in 33 (28.7%) cases. Additionally, 25 (21.7%) patients had a history of stroke, and 10 (8.7%) cases had a history of atrial fibrillation (AF) (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). Prior to admission, 44(37.4%) patients were on antiplatelet therapy. Anticoagulant use was reported in 16 (13.9%) cases (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). The remaining clinical and laboratory data were summarized in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>The study of patient characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Variable</th><th align="left" colspan="1" rowspan="1">Median (IQR)</th></tr></thead><tbody><tr><td align="left" colspan="2" rowspan="1">Baseline characteristics</td></tr><tr><td align="left" colspan="1" rowspan="1"> Age<sup>#</sup>, <italic toggle="yes">n</italic> = 115</td><td align="left" colspan="1" rowspan="1">68.71(14.75)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Gender<sup>*</sup>, Male, <italic toggle="yes">n</italic> = 115</td><td align="left" colspan="1" rowspan="1">72(63.47)</td></tr><tr><td align="left" colspan="1" rowspan="1"> BMI, <italic toggle="yes">n</italic> = 115</td><td align="left" colspan="1" rowspan="1">25.95(23.92-28.39)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Days in Hospital(days), <italic toggle="yes">n</italic> = 115</td><td align="left" colspan="1" rowspan="1">6 (4-8.5)</td></tr><tr><td align="left" colspan="2" rowspan="1"> Mode of transfer <sup>*</sup>, <italic toggle="yes">n </italic>= 115</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;EMS, male</td><td align="left" colspan="1" rowspan="1">71 (61.73), 46(63.9)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Private, male</td><td align="left" colspan="1" rowspan="1">40 (34.78), 25(34.7)</td></tr><tr><td align="left" colspan="1" rowspan="1"> In-hospital, male</td><td align="left" colspan="1" rowspan="1">2 (1.73), 1(1.4)</td></tr><tr><td align="left" colspan="2" rowspan="1">Vital signs</td></tr><tr><td align="left" colspan="1" rowspan="1"> SBP (mmHg), <italic toggle="yes">n</italic>=112</td><td align="left" colspan="1" rowspan="1">140 (128.5-165)</td></tr><tr><td align="left" colspan="1" rowspan="1"> DBP (mmHg), <italic toggle="yes">n</italic>=112</td><td align="left" colspan="1" rowspan="1">80 (78.5-93.5)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Heart rate (bpm), <italic toggle="yes">n</italic>=112</td><td align="left" colspan="1" rowspan="1">80 (70.5-86.5)</td></tr><tr><td align="left" colspan="2" rowspan="1">Stroke characteristic</td></tr><tr><td align="left" colspan="1" rowspan="1"> NIHSS Admission, <italic toggle="yes">n</italic> = 112</td><td align="left" colspan="1" rowspan="1">8.5 (4-13)</td></tr><tr><td align="left" colspan="1" rowspan="1"> NIHSS Discharge, <italic toggle="yes">n</italic> = 112</td><td align="left" colspan="1" rowspan="1">0 (0-4)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Anterior ASPECT, <italic toggle="yes">n</italic> = 103</td><td align="left" colspan="1" rowspan="1">9 (8-10)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Posterior ASPECT, <italic toggle="yes">n</italic> = 85</td><td align="left" colspan="1" rowspan="1">10 (10-10)</td></tr><tr><td align="left" colspan="2" rowspan="1">Outcome <sup>*</sup></td></tr><tr><td align="left" colspan="1" rowspan="1"> Alive</td><td align="left" colspan="1" rowspan="1">108(93.91)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Death</td><td align="left" colspan="1" rowspan="1">7(6.08)</td></tr><tr><td align="left" colspan="2" rowspan="1">Lab data</td></tr><tr><td align="left" colspan="1" rowspan="1"> WBC (x10&#179;/&#181;L), <italic toggle="yes">n</italic> = 91</td><td align="left" colspan="1" rowspan="1">8.1(7-10.45)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Hgb<sup>#</sup>(g/dL), <italic toggle="yes">n</italic> = 89</td><td align="left" colspan="1" rowspan="1">13.00(2.13)</td></tr><tr><td align="left" colspan="1" rowspan="1"> BUN (mg/dL), <italic toggle="yes">n</italic> = 85</td><td align="left" colspan="1" rowspan="1">37 (29-45)</td></tr><tr><td align="left" colspan="1" rowspan="1"> CR (mg/dL), <italic toggle="yes">n</italic> = 86</td><td align="left" colspan="1" rowspan="1">0.9 (0.8-1)</td></tr><tr><td align="left" colspan="1" rowspan="1"> HbA1C (%), <italic toggle="yes">n</italic> = 40</td><td align="left" colspan="1" rowspan="1">6.15 (5.5-7.35)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Sodium (mmol/L), <italic toggle="yes">n</italic> = 94</td><td align="left" colspan="1" rowspan="1">139 (137-142)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Potassium (mmol/L), <italic toggle="yes">n</italic> = 94</td><td align="left" colspan="1" rowspan="1">4 (3.7-4.3)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Cholesterol (mg/dL), <italic toggle="yes">n</italic> = 65</td><td align="left" colspan="1" rowspan="1">152 (122-180)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Triglycerides (mg/dL), <italic toggle="yes">n</italic> = 69</td><td align="left" colspan="1" rowspan="1">120 (96-170)</td></tr><tr><td align="left" colspan="1" rowspan="1"> HDL (mg/dL), <italic toggle="yes">n</italic> = 70</td><td align="left" colspan="1" rowspan="1">37 (33-42)</td></tr><tr><td align="left" colspan="1" rowspan="1"> LDL (mg/dL), <italic toggle="yes">n</italic> = 69</td><td align="left" colspan="1" rowspan="1">79 (56-117)</td></tr><tr><td align="left" colspan="1" rowspan="1"> ALT (U/L), <italic toggle="yes">n</italic> = 62</td><td align="left" colspan="1" rowspan="1">21 (15-31)</td></tr><tr><td align="left" colspan="1" rowspan="1"> AST (U/L), <italic toggle="yes">n</italic> = 62</td><td align="left" colspan="1" rowspan="1">22 (16-28)</td></tr><tr><td align="left" colspan="1" rowspan="1"> ALP (U/L), <italic toggle="yes">n</italic> = 60</td><td align="left" colspan="1" rowspan="1">201.5 (157.5-228)</td></tr><tr><td align="left" colspan="1" rowspan="1"> ESR (mm/hr), <italic toggle="yes">n</italic> = 69</td><td align="left" colspan="1" rowspan="1">20 (10-32)</td></tr><tr><td align="left" colspan="1" rowspan="1"> CRP (mg/L), <italic toggle="yes">n</italic> = 60</td><td align="left" colspan="1" rowspan="1">3 (1-17)</td></tr><tr><td align="left" colspan="1" rowspan="1"> PT, <italic toggle="yes">n</italic> = 78</td><td align="left" colspan="1" rowspan="1">13.2 (12.2-14)</td></tr><tr><td align="left" colspan="1" rowspan="1"> PTT, <italic toggle="yes">n</italic> = 83</td><td align="left" colspan="1" rowspan="1">26 (25-29)</td></tr><tr><td align="left" colspan="1" rowspan="1"> INR, <italic toggle="yes">n</italic> = 81</td><td align="left" colspan="1" rowspan="1">1.04 (1-1.14)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Platelets, <italic toggle="yes">n</italic> = 87</td><td align="left" colspan="1" rowspan="1">185 (148-213.5)</td></tr><tr><td align="left" colspan="2" rowspan="1">Time tracker (min)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Onset-to-Door, <italic toggle="yes">n</italic> = 103</td><td align="left" colspan="1" rowspan="1">90 (60-145)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Door-to-Stroke Team Visit, <italic toggle="yes">n</italic> = 107</td><td align="left" colspan="1" rowspan="1">0 (0-5)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Door-to-Imaging, <italic toggle="yes">n</italic> = 107</td><td align="left" colspan="1" rowspan="1">7 (3-15)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Door-to-Needle (DTN), <italic toggle="yes">n</italic> = 99</td><td align="left" colspan="1" rowspan="1">65 (48-84.5)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Door-to-Groin Puncture (DTP), <italic toggle="yes">n</italic> = 30</td><td align="left" colspan="1" rowspan="1">109 (75-158)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Stroke onset to treatment time</td><td align="left" colspan="1" rowspan="1">163(112.5-215)</td></tr></tbody></table><table-wrap-foot><p>*Data are presents as frequency (%) ; <sup>#</sup> Normally distributed data are presented as mean(SD); <italic toggle="yes">BMI </italic>Body mass index; <italic toggle="yes">EMS </italic>Emergency medical services; <italic toggle="yes">SBP </italic>Systolic blood pressure; <italic toggle="yes">DBP </italic>Diastolic blood pressure; <italic toggle="yes">NIHSS </italic>National Institutes of Health Stroke Scale; <italic toggle="yes">ASPECTS </italic>Alberta Stroke Program Early CT Score; <italic toggle="yes">WBC </italic>White blood cells; <italic toggle="yes">Hgb </italic>Hemoglobin; <italic toggle="yes">BUN </italic>Blood urea nitrogen; <italic toggle="yes">CR </italic>Creatinine; <italic toggle="yes">HbA1C </italic>Glycated hemoglobin; <italic toggle="yes">ALT </italic>Alanine aminotransferase; <italic toggle="yes">AST </italic>Aspartate aminotransferase; <italic toggle="yes">ALP </italic>Alkaline phosphatase; <italic toggle="yes">ESR </italic>Erythrocyte sedimentation rate; <italic toggle="yes">CRP </italic>C-reactive protein; <italic toggle="yes">PT </italic>Prothrombin time; <italic toggle="yes">PTT </italic>Partial thromboplastin time; <italic toggle="yes">INR </italic>International normalized ratio; <italic toggle="yes">DTN </italic>Door-to-needle time; <italic toggle="yes">DTP </italic>Door-to-puncture time</p></table-wrap-foot></table-wrap><table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Clinical characteristics of patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Variables (<italic toggle="yes">n</italic>=115)</th><th align="left" colspan="1" rowspan="1">Frequency (%)</th></tr></thead><tbody><tr><td align="left" colspan="2" rowspan="1">Sign and symptoms</td></tr><tr><td align="left" colspan="1" rowspan="1"> Hemiparesis/Monoparesis</td><td align="left" colspan="1" rowspan="1">91(79.1)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Hemisensory Deficit</td><td align="left" colspan="1" rowspan="1">6(5.2)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Monocular/Binocular visual loss</td><td align="left" colspan="1" rowspan="1">1(0.9)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Visual field deficits</td><td align="left" colspan="1" rowspan="1">4(3.5)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Dysarthria</td><td align="left" colspan="1" rowspan="1">51(44.3)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Facial droop</td><td align="left" colspan="1" rowspan="1">66(57.4)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Ataxia/Incoordination/Gait instability</td><td align="left" colspan="1" rowspan="1">9(7.8)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Vertigo</td><td align="left" colspan="1" rowspan="1">8(7)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Dizziness</td><td align="left" colspan="1" rowspan="1">1(0.9)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Gaze deviation</td><td align="left" colspan="1" rowspan="1">7(6.1)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Dysphagia</td><td align="left" colspan="1" rowspan="1">5(4.3)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Aphasia</td><td align="left" colspan="1" rowspan="1">43(37.4)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Decrease in LOC</td><td align="left" colspan="1" rowspan="1">17(14.8)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Incontinency</td><td align="left" colspan="1" rowspan="1">2(1.7)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Nausea/Vomiting</td><td align="left" colspan="1" rowspan="1">6(5.2)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Falling</td><td align="left" colspan="1" rowspan="1">14(12.2)</td></tr><tr><td align="left" colspan="2" rowspan="1">Past medical history</td></tr><tr><td align="left" colspan="1" rowspan="1"> History of stroke</td><td align="left" colspan="1" rowspan="1">25(21.7)</td></tr><tr><td align="left" colspan="1" rowspan="1"> History of TIA</td><td align="left" colspan="1" rowspan="1">3(2.6)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Hypertension</td><td align="left" colspan="1" rowspan="1">77(67)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Diabetes mellitus</td><td align="left" colspan="1" rowspan="1">39(33.9)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Dyslipidemia</td><td align="left" colspan="1" rowspan="1">16(13.9)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Ischemic heart disease</td><td align="left" colspan="1" rowspan="1">33(28.7)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Heart failure</td><td align="left" colspan="1" rowspan="1">3(2.6)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Chronic kidney disease</td><td align="left" colspan="1" rowspan="1">2(1.7)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Atrial fibrillation</td><td align="left" colspan="1" rowspan="1">10(8.7)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Smoking history</td><td align="left" colspan="1" rowspan="1">12(10.4)</td></tr><tr><td align="left" colspan="2" rowspan="1">Drug history</td></tr><tr><td align="left" colspan="2" rowspan="1"> Antiplatelet</td></tr><tr><td align="left" colspan="1" rowspan="1"> Aspirin</td><td align="left" colspan="1" rowspan="1">41(35.7)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Clopidogrel</td><td align="left" colspan="1" rowspan="1">25(21.7)</td></tr><tr><td align="left" colspan="2" rowspan="1"> Anticoagulant</td></tr><tr><td align="left" colspan="1" rowspan="1"> Heparin</td><td align="left" colspan="1" rowspan="1">2(1.7)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Warfarin</td><td align="left" colspan="1" rowspan="1">6(5.2)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Apixaban</td><td align="left" colspan="1" rowspan="1">2(1.7)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Rivaroxaban</td><td align="left" colspan="1" rowspan="1">4(3.5)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Antihypertensive</td><td align="left" colspan="1" rowspan="1">65(56.5)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Antidiabetic</td><td align="left" colspan="1" rowspan="1">27(23.5)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Lipid lowering</td><td align="left" colspan="1" rowspan="1">37(32.2)</td></tr><tr><td align="left" colspan="2" rowspan="1"> Hormone therapy</td></tr><tr><td align="left" colspan="1" rowspan="1"> HRT</td><td align="left" colspan="1" rowspan="1">7(6.1)</td></tr><tr><td align="left" colspan="1" rowspan="1"> OCP</td><td align="left" colspan="1" rowspan="1">1(0.9)</td></tr><tr><td align="left" colspan="2" rowspan="1">Pattern of deficit&#160;</td></tr><tr><td align="left" colspan="1" rowspan="1">Fluctuating</td><td align="left" colspan="1" rowspan="1">6(5.2)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Immediately complete</td><td align="left" colspan="1" rowspan="1">73(63.5)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Progressive</td><td align="left" colspan="1" rowspan="1">5(4.3)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Rapidly resolved</td><td align="left" colspan="1" rowspan="1">16(13.9)</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">LOC</italic>&#160;Level of consciousness; <italic toggle="yes">TIA</italic>&#160;Transient ischemic attack; <italic toggle="yes">HRT</italic>&#160;Hormone replacement therapy; <italic toggle="yes">OCP</italic>&#160;Oral contraceptive pill</p></table-wrap-foot></table-wrap></p><p id="Par26">Based on the Trial of Org 10,172 in Acute Stroke Treatment (TOAST) classification, the most common stroke subtype was Undetermined etiology observed in 38 patients (33%). Large artery atherosclerosis was the second most frequent, comprising 29 patients (25.2%), followed by small vessel (20.9%) strokes in 24 patients. Cardioembolic stroke, including cases related to rheumatic and non-rheumatic valvular disease or coronary artery disease, was identified in 21 patients (18.3%). Stroke due to other determined etiologies was the least common occurring in only 3 patients (2.6%) (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Frequency of TOAST classification</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">TOAST category</th><th align="left" colspan="1" rowspan="1">IVT (<italic toggle="yes">n</italic> = 81)</th><th align="left" colspan="1" rowspan="1">Bridge (<italic toggle="yes">n</italic> = 26)</th><th align="left" colspan="1" rowspan="1">MT (<italic toggle="yes">n</italic> = 8)</th><th align="left" colspan="1" rowspan="1">Total (<italic toggle="yes">n</italic> = 115)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Cardioembolic</td><td align="left" colspan="1" rowspan="1">14 (17.3)</td><td align="left" colspan="1" rowspan="1">7 (26.9)</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">22 (18.3)</td></tr><tr><td align="left" colspan="1" rowspan="1">Large artery</td><td align="left" colspan="1" rowspan="1">16 (19.8)</td><td align="left" colspan="1" rowspan="1">10 (38.5)</td><td align="left" colspan="1" rowspan="1">3 (37.5)</td><td align="left" colspan="1" rowspan="1">29 (25.2)</td></tr><tr><td align="left" colspan="1" rowspan="1">Small vessel (Lacunar)</td><td align="left" colspan="1" rowspan="1">23 (28.4)</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">1 (12.5)</td><td align="left" colspan="1" rowspan="1">24 (20.9)</td></tr><tr><td align="left" colspan="1" rowspan="1">Undetermined</td><td align="left" colspan="1" rowspan="1">27 (33.3)</td><td align="left" colspan="1" rowspan="1">7 (26.9)</td><td align="left" colspan="1" rowspan="1">4 (50.0)</td><td align="left" colspan="1" rowspan="1">38 (33)</td></tr><tr><td align="left" colspan="1" rowspan="1">Other determined</td><td align="left" colspan="1" rowspan="1">1 (1.2)</td><td align="left" colspan="1" rowspan="1">2 (7.7)</td><td align="left" colspan="1" rowspan="1">0</td><td align="left" colspan="1" rowspan="1">3 (2.6)</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">IVT</italic> Intravenous thrombolysis; <italic toggle="yes">MT</italic> Mechanical thrombectomy</p></table-wrap-foot></table-wrap></p><p id="Par27">The median (IQR) of NIHSS score at admission was 8.5 (4&#8211;13), which improved to 0 (0&#8211;4) at discharge. (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>).</p><p id="Par28">Imaging findings of 115 patients showed middle cerebral artery (MCA) occlusion was the most affected artery, followed by internal carotid artery. Detailed imaging findings present in Table&#160;<xref rid="Tab4" ref-type="table">4</xref>.<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Imaging findings</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Imaging type</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">N</italic></th><th align="left" colspan="1" rowspan="1">Normal* (%)</th><th align="left" colspan="1" rowspan="1">Specific findings</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Chest CT</td><td align="left" colspan="1" rowspan="1">115</td><td align="left" colspan="1" rowspan="1">93</td><td align="left" colspan="1" rowspan="1">Aspiration Pneumonia (3.5%), Pleural Effusion (1.7%), Parenchymal Disease (0.9%), COVID-19 (1.7%)</td></tr><tr><td align="left" colspan="1" rowspan="1">MRI</td><td align="left" colspan="1" rowspan="1">27</td><td align="left" colspan="1" rowspan="1">37.0</td><td align="left" colspan="1" rowspan="1">MCA Infarct (40.7%), ACA Infarct (7.4%), PCA Infarct (3.7%), Subcortical Infarct (14.8%), Brainstem Lesions (7.4%), Cerebellum lesions (7.4%)</td></tr><tr><td align="left" colspan="1" rowspan="1">CTA</td><td align="left" colspan="1" rowspan="1">75</td><td align="left" colspan="1" rowspan="1">33.9</td><td align="left" colspan="1" rowspan="1">MCA Occlusion (18.3%), ICA Occlusion (13.9%), ACA Occlusion (0.9%), Vertebral Occlusion (0.9%)</td></tr><tr><td align="left" colspan="1" rowspan="1">DSA</td><td align="left" colspan="1" rowspan="1">26</td><td align="left" colspan="1" rowspan="1">30.8</td><td align="left" colspan="1" rowspan="1">MCA Stenosis (8.7%), ICA Stenosis (5.2%), Basilar Stenosis (0.9%)</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">CT</italic>&#8201;Computed tomography; <italic toggle="yes">MRI</italic>&#8201;Magnetic resonance imaging; <italic toggle="yes">CTA</italic>&#8201;CT angiography; <italic toggle="yes">DSA</italic>&#8201;Digital subtraction angiography; <italic toggle="yes">MCA</italic>&#8201;Middle cerebral artery; <italic toggle="yes">ACA</italic>&#8201;Anterior cerebral artery; <italic toggle="yes">PCA</italic>&#8201;Posterior cerebral artery; <italic toggle="yes">ICA</italic>&#8201;Internal carotid artery</p><p>*</p></table-wrap-foot></table-wrap></p><p id="Par29">Of the 115 patients analyzed, 7 (6.1%) experienced cerebral edema, 9 (7.8%) had hemorrhagic transformation, and 2 (1.7%) had remote intracerebral hemorrhage. Overall, 109 patients (94.8%) did not experience any complications (Table&#160;<xref rid="Tab5" ref-type="table">5</xref>).<table-wrap id="Tab5" position="float" orientation="portrait"><label>Table 5</label><caption><p>Frequency of complications related to treatment</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Complication</th><th align="left" colspan="1" rowspan="1">IVT (<italic toggle="yes">n</italic> = 81)</th><th align="left" colspan="1" rowspan="1">Bridge (<italic toggle="yes">n</italic> = 26)</th><th align="left" colspan="1" rowspan="1">MT (<italic toggle="yes">n</italic> = 8)</th><th align="left" colspan="1" rowspan="1">Total (<italic toggle="yes">n</italic> = 115)</th></tr><tr><th align="left" colspan="4" rowspan="1"><italic toggle="yes">N</italic> (%)</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Cerebral edema</td><td align="left" colspan="1" rowspan="1">1 (1.2)</td><td align="left" colspan="1" rowspan="1">5 (30.8)</td><td align="left" colspan="1" rowspan="1">1 (12.5)</td><td align="left" colspan="1" rowspan="1">7 (6.1)</td></tr><tr><td align="left" colspan="1" rowspan="1">Hemorrhagic transformation</td><td align="left" colspan="1" rowspan="1">1 (7.8)</td><td align="left" colspan="1" rowspan="1">8 (30.8)</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">9 (7.8)</td></tr><tr><td align="left" colspan="1" rowspan="1">Remote ICH</td><td align="left" colspan="1" rowspan="1">2 (2.5)</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">2 (1.7)</td></tr><tr><td align="left" colspan="1" rowspan="1">Re-infarction</td><td align="left" colspan="1" rowspan="1">1 (1.2)</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">1 (0.9)</td></tr><tr><td align="left" colspan="1" rowspan="1">Extracranial bleeding</td><td align="left" colspan="1" rowspan="1">3 (3.7)</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">3 (2.6)</td></tr><tr><td align="left" colspan="1" rowspan="1">Seizure</td><td align="left" colspan="1" rowspan="1">1 (1.2)</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">-</td><td align="left" colspan="1" rowspan="1">1 (0.9)</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">ICH</italic> Intracranial hemorrhage; <italic toggle="yes">IVT</italic> Intravenous thrombolysis; <italic toggle="yes">MT</italic> Mechanical thrombectomy</p></table-wrap-foot></table-wrap></p><p id="Par30">The median (IQR) door-to-needle time (DTN) was 65 (48-84.5) minutes, while the median door-to-groin puncture time (DTP) for thrombectomy patients was 109 (IQR: 75&#8211;158) minutes (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>).</p><p id="Par31">Among the 115 patients, 50 (42.5%) experienced delays in receiving timely therapy. Patient-related delays were observed in 12 patients (10.4%), including initial patient refusal (9.6%) and lack of a companion (0.9%). Medical conditions contributed to delays in another 12 patients (10.4%). Hospital-related delays were reported in 44 patients (38.3%), with the most common cause being personnel issues (32.2%), followed by equipment-related delays (10.4%) and mis-triage of stroke patients (6.1%) (Table&#160;<xref rid="Tab6" ref-type="table">6</xref>).<table-wrap id="Tab6" position="float" orientation="portrait"><label>Table 6</label><caption><p>Reasons for prolonged door-to-needle time/door-to-puncture time</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left" colspan="1" rowspan="1">Reasons for prolonged DTN (&gt;60min)</td><td align="left" colspan="1" rowspan="1">IVT (<italic toggle="yes">n</italic> = 81) </td><td align="left" colspan="1" rowspan="1">Bridge (<italic toggle="yes">n</italic> = 26)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="2" rowspan="1"><italic toggle="yes">N</italic> (%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Patient</td><td align="left" colspan="1" rowspan="1">8 (9.9)</td><td align="left" colspan="1" rowspan="1">4 (15.4)</td></tr><tr><td align="left" colspan="1" rowspan="1">Medical conditions</td><td align="left" colspan="1" rowspan="1">7 (8.6)</td><td align="left" colspan="1" rowspan="1">4 (15.4)</td></tr><tr><td align="left" colspan="1" rowspan="1">Hospital delay</td><td align="left" colspan="1" rowspan="1">31 (38.3)</td><td align="left" colspan="1" rowspan="1">12 (46.2)</td></tr><tr><td align="left" colspan="1" rowspan="1">Hospital-personnel delay</td><td align="left" colspan="1" rowspan="1">26 (32.1)</td><td align="left" colspan="1" rowspan="1">11 (42.3)</td></tr><tr><td align="left" colspan="1" rowspan="1">Hospital-equipment delay</td><td align="left" colspan="1" rowspan="1">4 (9.9)</td><td align="left" colspan="1" rowspan="1">2 (7.7)</td></tr><tr><td align="left" colspan="1" rowspan="1">Total number delay</td><td align="left" colspan="1" rowspan="1">34 (42)</td><td align="left" colspan="1" rowspan="1">14 (53.8)</td></tr><tr><td align="left" rowspan="2" colspan="1">Reason for prolonged DTP (&gt;120 min)</td><td align="left" colspan="2" rowspan="1">Bridge (<italic toggle="yes">n</italic> = 26)</td></tr><tr><td align="left" colspan="2" rowspan="1"><italic toggle="yes">N</italic> (%)</td></tr><tr><td align="left" colspan="1" rowspan="1">Patient refusal</td><td align="left" colspan="1" rowspan="1">1 (3.8)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Medical conditions</td><td align="left" colspan="1" rowspan="1">1 (3.8)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Personnel delay</td><td align="left" colspan="1" rowspan="1">3 (11.5)</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Equipment delay</td><td align="left" colspan="1" rowspan="1">2 (7.7)</td><td align="left" colspan="1" rowspan="1"/></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">N</italic> Number of participants. There was no delay in mechanical thrombectomy. There was no prolonged DTP in MT group. <italic toggle="yes">IVT</italic> Intravenous thrombolysis; <italic toggle="yes">MT</italic> Mechanical thrombectomy; <italic toggle="yes">DTN</italic> Door to needle; <italic toggle="yes">DTP</italic> Door to puncture</p></table-wrap-foot></table-wrap></p><p id="Par32">Overall, these findings emphasize the need for targeted improvements in hospital workflow and patient education to minimize delays and optimize treatment outcomes.</p></sec><sec id="Sec10"><title>Key related factors of outcomes</title><p id="Par33">A total of 110 patients were included in the multiple linear regression analysis. Cases with missing data (e.g., NIHSS at admission/discharge, treatment-related complications, or baseline characteristics) were excluded to ensure robustness (<italic toggle="yes">n</italic>&#8201;=&#8201;5).</p><p id="Par34">A multiple linear regression was performed to examine the extent to which age, DBP, NIHSS at admission, and treatment-related complications predicted NIHSS score at discharge. The overall model was statistically significant, <italic toggle="yes">F</italic>(4, 105)&#8201;=&#8201;16.84, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001, and demonstrated a multiple correlation coefficient (R) of 0.625, with an R<sup>2</sup>&#160;of 0.391, suggesting that approximately 39.1% of the variance in anterior NIHSS at discharge was explained by the associated factors.</p><p id="Par35">Among the variables included in the model, NIHSS at admission emerged as the strongest independent factor associated with the outcome (B&#8201;=&#8201;0.685, &#946;&#8201;=&#8201;0.374, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001), indicating that each one-point increase in admission NIHSS was associated with a 0.69-point increase in NIHSS at discharge. Treatment-related complications were also significantly associated with worse functional outcomes (B&#8201;=&#8201;6.904, &#946;&#8201;=&#8201;0.265, <italic toggle="yes">p</italic>&#8201;=&#8201;0.002), suggesting a clinically meaningful increase in discharge severity among those experiencing complications. Age was a modest but statistically significant factor associated with the outcome (B&#8201;=&#8201;0.118, SE&#8201;=&#8201;0.052, &#946;&#8201;=&#8201;0.177, <italic toggle="yes">p</italic>&#8201;=&#8201;0.025). DBP was not significantly associated with the outcome (B&#8201;=&#8201;0.069, SE&#8201;=&#8201;0.051, &#946;&#8201;=&#8201;0.107, <italic toggle="yes">p</italic>&#8201;=&#8201;0.176) (Table&#160;<xref rid="Tab7" ref-type="table">7</xref>).<table-wrap id="Tab7" position="float" orientation="portrait"><label>Table 7</label><caption><p>Multiple linear regression analysis predicting functional outcome (NIHSS at Discharge) in patients with acute ischemic stroke</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Predictors</th><th align="left" colspan="3" rowspan="1">Simple regression (unadjusted)</th><th align="left" colspan="3" rowspan="1">Multiple regression (adjusted)</th></tr><tr><th align="left" colspan="1" rowspan="1">Std. &#946;</th><th align="left" colspan="1" rowspan="1">SE</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-value</th><th align="left" colspan="1" rowspan="1">Std. &#946;</th><th align="left" colspan="1" rowspan="1">SE</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Age (year)</td><td align="left" colspan="1" rowspan="1">0.266</td><td align="left" colspan="1" rowspan="1">0.060</td><td align="left" colspan="1" rowspan="1"><bold>0.005</bold></td><td align="left" colspan="1" rowspan="1">0.177</td><td align="left" colspan="1" rowspan="1">0.052</td><td align="left" colspan="1" rowspan="1"><bold>0.025</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">Gender (ref. female)</td><td align="left" colspan="1" rowspan="1">0.062</td><td align="left" colspan="1" rowspan="1">1.87</td><td align="left" colspan="1" rowspan="1">0.516</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Days in hospital</td><td align="left" colspan="1" rowspan="1">0.034</td><td align="left" colspan="1" rowspan="1">0.101</td><td align="left" colspan="1" rowspan="1">0.725</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">BMI</td><td align="left" colspan="1" rowspan="1">&#8722;0.053</td><td align="left" colspan="1" rowspan="1">0.022</td><td align="left" colspan="1" rowspan="1">0.578</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="7" rowspan="1">Mode of transfer (ref. EMS)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Private</td><td align="left" colspan="1" rowspan="1">&#8722;0.149</td><td align="left" colspan="1" rowspan="1">1.93</td><td align="left" colspan="1" rowspan="1">0.123</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"> In-hospital</td><td align="left" colspan="1" rowspan="1">&#8722;0.057</td><td align="left" colspan="1" rowspan="1">4.93</td><td align="left" colspan="1" rowspan="1">0.549</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">SBP (mmHg) &#8224;</td><td align="left" colspan="1" rowspan="1">0.193</td><td align="left" colspan="1" rowspan="1">0.034</td><td align="left" colspan="1" rowspan="1"><bold>0.046</bold></td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">DBP (mmHg)</td><td align="left" colspan="1" rowspan="1">0.243</td><td align="left" colspan="1" rowspan="1">0.061</td><td align="left" colspan="1" rowspan="1"><bold>0.014</bold></td><td align="left" colspan="1" rowspan="1">0.107</td><td align="left" colspan="1" rowspan="1">0.051</td><td align="left" colspan="1" rowspan="1">0.176</td></tr><tr><td align="left" colspan="1" rowspan="1">Heart Rate</td><td align="left" colspan="1" rowspan="1">&#8722;0.060</td><td align="left" colspan="1" rowspan="1">0.071</td><td align="left" colspan="1" rowspan="1">0.531</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Ant. ASPECT <sup>*</sup></td><td align="left" colspan="1" rowspan="1">&#8722;0.282</td><td align="left" colspan="1" rowspan="1">0.427</td><td align="left" colspan="1" rowspan="1"><bold>0.005</bold></td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Post. ASPECT</td><td align="left" colspan="1" rowspan="1">&#8722;0.023</td><td align="left" colspan="1" rowspan="1">3.35</td><td align="left" colspan="1" rowspan="1">0.835</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">NIHSS on admission</td><td align="left" colspan="1" rowspan="1">0.529</td><td align="left" colspan="1" rowspan="1">0.148</td><td align="left" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td><td align="left" colspan="1" rowspan="1">0.374</td><td align="left" colspan="1" rowspan="1">0.156</td><td align="left" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td></tr><tr><td align="left" colspan="1" rowspan="1">DTN</td><td align="left" colspan="1" rowspan="1">&#8722;0.052</td><td align="left" colspan="1" rowspan="1">0.016</td><td align="left" colspan="1" rowspan="1">0.616</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="7" rowspan="1">TOAST-class (ref. undetermined)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Large artery</td><td align="left" colspan="1" rowspan="1">0.068</td><td align="left" colspan="1" rowspan="1">2.37</td><td align="left" colspan="1" rowspan="1">0.530</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"> Small vessel (lacunar)</td><td align="left" colspan="1" rowspan="1">&#8722;0.189</td><td align="left" colspan="1" rowspan="1">2.55</td><td align="left" colspan="1" rowspan="1">0.078</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"> Cardiometabolic</td><td align="left" colspan="1" rowspan="1">&#8722;0.067</td><td align="left" colspan="1" rowspan="1">2.59</td><td align="left" colspan="1" rowspan="1">0.528</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"> Other determined</td><td align="left" colspan="1" rowspan="1">&#8722;0.053</td><td align="left" colspan="1" rowspan="1">5.72</td><td align="left" colspan="1" rowspan="1">0.581</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="7" rowspan="1">Treatment -related complications (ref. No)</td></tr><tr><td align="left" colspan="1" rowspan="1"> Yes</td><td align="left" colspan="1" rowspan="1">0.439</td><td align="left" colspan="1" rowspan="1">2.186</td><td align="left" colspan="1" rowspan="1"><bold>&lt;&#8201;0.001</bold></td><td align="left" colspan="1" rowspan="1">0.265</td><td align="left" colspan="1" rowspan="1">2.15</td><td align="left" colspan="1" rowspan="1"><bold>0.002</bold></td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">NIHSS</italic>&#8201;National Institutes of Health Stroke Scale; <italic toggle="yes">&#946;</italic>&#8201;Regression coefficient (change in NIHSS per unit predictor increase); <italic toggle="yes">SE</italic>&#8201;Standard error (precision of &#946; estimate); <italic toggle="yes">DBP</italic>&#8201;Diastolic blood pressure (mmHg); <italic toggle="yes">ref.</italic>&#160;Reference category</p><p>&#8224; was excluded due to collinearity with diastolic blood pressure (DBP), as DBP provided a better model fit</p><p>*Anterior ASPECT score was excluded because its inclusion substantially reduced the sample size (<italic toggle="yes">n</italic>&#8201;=&#8201;100), compromising model stability. The final model demonstrated improved fit without this variable</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec11"><title>Discussion</title><p id="Par36">The present cohort of 115 thrombolysis/thrombectomy-eligible cases drawn from the ETRAISI, the first established stroke registry at the referral crowded hospital, shows a &#8220;real-world&#8221; elderly population with a marked male preponderance (62.6%). When benchmarked against the SITS-ISTR Middle East subset (mean age 65 yrs; male 60%) [<xref ref-type="bibr" rid="CR19">19</xref>], the demographic window is highly comparable, supporting external validity for regional stroke-care audits. Notably, the mean age observed is also consistent with findings from sub-Saharan Africa, where stroke tends to occur at a younger age compared to high-income countries, where the median age at stroke onset typically exceeds 70 years [<xref ref-type="bibr" rid="CR20">20</xref>]. This supports the growing body of evidence that stroke poses a substantial and earlier burden in low- and middle-income regions likely due to delayed detection of the risk factor progression and lifestyle modification. Like other registries, HTN and DM are the most common risk factors associated with acute AIS. Although our prevalence of HTN and DM is slightly higher than that reported in the SITS-UTMOST registry and similar to the Malaysian report, we believe that poor control of these risk factors contributes to the increased risk of AIS in patients. Additionally, ischemic heart disease (IHD) ranks third as a risk factor in our study, with a much higher prevalence (28%) compared to other registries (&#8776;&#8201;12%). Therefore, policymakers should consider stricter control of these risk factors to reduce the prevalence of AIS [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. we deserve notice the atrial-fibrillation prevalence (8.7%) is roughly one-third of that reported in European registries (&#8776;&#8201;25%) [<xref ref-type="bibr" rid="CR23">23</xref>], which might show under-diagnosis AF onset in Iran [<xref ref-type="bibr" rid="CR24">24</xref>].</p><p id="Par37">Consistent with other registries, the frequencies of TOAST classifications&#8212;such as small vessel occlusion, cardioembolic, and other determined etiologies&#8212;fall within a similar range [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. However, large-artery atherosclerosis dominated our TOAST distribution (25.2%), though this was slightly lower than the 30&#8211;35% reported in pooled meta-analyses for Asian population [<xref ref-type="bibr" rid="CR27">27</xref>]. In our registry, it ranked second, whereas in the Riga, SITS [<xref ref-type="bibr" rid="CR25">25</xref>], and CRCS-K-NIH registries [<xref ref-type="bibr" rid="CR26">26</xref>], large-artery atherosclerosis was the most common subtype. Additionally, while the &#8220;undetermined&#8221; category constituted a substantial proportion (33%) in our study, these registries reported a much lower prevalence.</p><p id="Par38">Notably, TOAST classification distribution varies across age groups. For instance, in juvenile stroke, certain etiologies are more prominent, whereas in older populations, small vessel occlusion and cardioembolic causes account for a larger proportion [<xref ref-type="bibr" rid="CR28">28</xref>]. The high percentage of undetermined cases in our registry may reflect geographic differences or persistent limitations in completing advanced diagnostic workups&#8212;such as prolonged rhythm monitoring, vasculitis panels, or prothrombotic screens&#8212;in busy public hospitals. Finally, the fact that 20.9% of cases were lacunar yet still received IVT aligns with contemporary evidence demonstrating that small-vessel occlusions can benefit from alteplase when treated within the appropriate imaging time window [<xref ref-type="bibr" rid="CR29">29</xref>].</p><p id="Par39">Regarding workflow metrics and modifiable delays, patient delay in seeking help constitutes the largest portion of overall treatment delay, emphasizing the need for improved patient education. Additionally, our observed median DTN of 65&#160;min exceeds the &#8220;&lt;60 minute&#8221; target recommended by the 2019 AHA guidelines [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. Although the median DTP of 109&#160;min does not exceed the recommended&#8201;&lt;&#8201;120&#160;min benchmark, this finding should not be considered conclusive due to single center report, small sample size, and the wide IQR range (75&#8211;158&#160;min), which reflects the complexity of case-by-case decision-making [<xref ref-type="bibr" rid="CR31">31</xref>]. Deconstructing DTN and DTP delay sources shows a predominant hospital component (38.3%), with personnel-related bottlenecks (32.2%) far outweighing equipment or lab issues. Despite activation of healthcare system following the initial &#8220;SAMA code&#8221; alert [<xref ref-type="bibr" rid="CR8">8</xref>], we propose that the key contributors to hospital delay include: (&#1110;) the over-loaded hospital capacity, and (ii)insufficient health care providers (iii), and lack of real-time dashboard feedback displayed in the ED to nudge competition between shifts [<xref ref-type="bibr" rid="CR32">32</xref>].</p><p id="Par40">On the safety profile of reperfusion, treatment related complication rates were low.The sICH figure lands within the 6&#8211;8% range of large RCTs [<xref ref-type="bibr" rid="CR33">33</xref>], while the combined hemorrhagic transformation&#8201;+&#8201;extracranial bleeding (10.4%) remains acceptable given a median NIHSS of 9 at baseline. The data therefore reinforce the safety of reperfusion in a resource-constrained setting, provided that blood-pressure targets (&lt;&#8201;180/105 mmHg) and glucose control are met&#8212;an area where 53% antihypertensive usage still leaves room for protocol tightening.</p><p id="Par41">The stroke care system in Iran operates on a referral-based model. Comprehensive Stroke Centers (CSCs) serve as &#8220;mothership&#8221; hubs, equipped for mechanical thrombectomy and advanced stroke management. &#8220;Drip-and-ship&#8221; centers focus on stabilizing patients and administering IV rtPA&#8212;when indicated and approved by a neurologist&#8212;before transferring them to a mothership center [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR34">34</xref>].</p><p id="Par42">In many low- and middle-income regions, the geographical reach and population coverage of this system remain far below those of high-income countries [<xref ref-type="bibr" rid="CR35">35</xref>]. Evidence shows that patients treated directly at mothership centers achieve better outcomes than those referred from primary centers [<xref ref-type="bibr" rid="CR34">34</xref>]. Yet, despite its proven benefits, access to mechanical thrombectomy remains limited worldwide&#8212;and the gap between low-/middle- and high-income settings is substantial [<xref ref-type="bibr" rid="CR35">35</xref>].</p><p id="Par43">Our study was conducted in a single mothership center, so there is no precise data on the prevalence of large vessel occlusion (LVO) in acute ischemic stroke (AIS) within our region. Based on previous studies, we estimate that approximately 25&#8211;50% of AIS cases involve LVO and could be candidates for MT [<xref ref-type="bibr" rid="CR36">36</xref>]. In contrast, only 7% of patients in our center underwent MT, and 22.6% underwent bridging therapy, for a total of approximately 30% receiving endovascular thrombectomy (EVT). Thus, as a mothership center, we are relatively close to covering the eligible patient population for EVT.</p><p id="Par44">However, these findings should be interpreted with caution. Accurate assessment requires collaboration between Primary Stroke Centers (PSCs) and CSCs to address challenges such as the limited number of neuro-interventionists and CSC facilities [<xref ref-type="bibr" rid="CR36">36</xref>], as well as to collect precise data on how delayed EVT or indirect transfers from PSCs may worsen patient prognosis [<xref ref-type="bibr" rid="CR34">34</xref>].</p><p id="Par45">The center&#8217;s protocol mandates aspirin 24&#160;h after alteplase, contingent on a hemorrhage-free follow-up CT, in line with AHA/ASA and ESO guidelines that recommend 160&#8211;300&#160;mg of aspirin within 24&#8211;48&#160;h to reduce early recurrent ischemia [<xref ref-type="bibr" rid="CR11">11</xref>]. Although the TREAT trial suggested that very-early ticagrelor&#8211;aspirin combinations may further reduce micro-embolic signals, current evidence does not justify dual therapy in the first 24&#160;h after rTPA because of heightened haemorrhagic risk; the single-agent approach used here is therefore appropriate [<xref ref-type="bibr" rid="CR37">37</xref>].</p><p id="Par46">Early initiation of high-intensity atorvastatin (40&#8211;80&#160;mg) conforms to SPARCL-derived class-I recommendations for secondary prevention, irrespective of baseline LDL [<xref ref-type="bibr" rid="CR38">38</xref>]. Beyond lipid lowering, pleiotropic effects&#8212;improved endothelial nitric-oxide bioavailability, anti-inflammatory action, and plaque stabilization [<xref ref-type="bibr" rid="CR39">39</xref>]&#8212;may contribute to the favorable reduction in three-month mRS observed in observational cohorts. Nonetheless, systematic lipid profiling on admission would allow personalized targets (&lt;&#8201;70&#160;mg dL&#8315;&#185;) and facilitate subsequent PCSK-9 or ezetimibe escalation in very-high-risk patients.</p><p id="Par47">Concomitant prescription of pantoprazole addresses gastrointestinal bleeding&#8212;a non-trivial risk after thrombolysis, especially in elderly hypertensives already committed to aspirin. The choice of pantoprazole over omeprazole minimises CYP2C19 interaction with clopidogrel in patients who may later require dual antiplatelet therapy for carotid stenting or coronary disease [<xref ref-type="bibr" rid="CR40">40</xref>].</p><p id="Par48">Regarding venous thrombo-embolism, the protocol provides both intermittent pneumatic compression during the first 24&#160;h (when pharmacologic prophylaxis is contraindicated) and low-dose low-molecular-weight heparin thereafter, mirroring outcomes from the CLOTS-3 study that showed a 35% relative reduction in proximal DVT without excess intracranial bleeding [<xref ref-type="bibr" rid="CR41">41</xref>]. Routine compression-device adherence audits, however, would ensure that the intervention&#8217;s efficacy is not diluted by application gaps.</p><p id="Par49">All patients undergo a bedside dysphagia screen before oral intake, an intervention repeatedly linked to halving pneumonia rates; NG-tube placement in failures ensures timely enteral nutrition while preventing aspiration. Introducing a validated tool such as the Gugging Swallow Screen [<xref ref-type="bibr" rid="CR42">42</xref>]&#8212;and documenting pass/fail rates&#8212;would allow benchmarking against international stroke units where &#8805;&#8201;95% screening compliance is now a quality indicator.</p><p id="Par50">Finally, Rapid detection of silent atrial fibrillation or high-grade carotid stenosis using the 12-lead ECG and transthoracic echocardiography permits early secondary-prevention decisions (oral anticoagulation, endarterectomy/stenting). Nonetheless, the diagnostic yield of a single ECG is modest; incorporating 24-hour telemetry or seven-day Holter monitoring&#8212;shown in the CRYSTAL-AF trials to treble AF detection [<xref ref-type="bibr" rid="CR43">43</xref>]&#8212;would capture paroxysmal arrhythmias that the current algorithm might miss.</p><sec id="Sec12"><title>Study strength and limitations</title><p id="Par51">A major strength of this study is the hospital-based design: data were entered in real time by dedicated stroke-nurse abstractors, minimizing recall bias and missing timestamps. Unlike many single-center audits that confine themselves to &#8220;door-to-needle&#8221;, the present registry captures a full treatment continuum&#8212;pre-hospital transport modality, laboratory variables, procedural times for IVT and MT, and early complications&#8212;allowing a systems-level view of acute-stroke care. The inclusion of TOAST adjudication for every case further elevates the dataset; most Middle Eastern series rely solely on ICD codes and cannot examine etiology-specific differences in delay or outcome. The study is not without weaknesses. Its single-center nature means workflow bottlenecks&#8212;particularly personnel delays&#8212;may reflect idiosyncratic staffing patterns rather than national norms; multi-center pooling would widen applicability. The sample size (<italic toggle="yes">n</italic>&#8201;=&#8201;115), while respectable for a detailed registry, is underpowered for granular subgroup analyses (e.g., bridging versus direct MT in cardio-embolic strokes). Lastly, outcome assessment stops at discharge; without a 90-day mRS or TICI for MT, we cannot determine whether early neurological improvement translates into durable functional independence.</p></sec></sec><sec id="Sec13"><title>Conclusion</title><p id="Par52">The ETRAISI registry offers a comprehensive evaluation of acute stroke care at a tertiary Iranian center, demonstrating both the successes and challenges of implementing guideline-directed reperfusion therapy. Despite resource limitations, the registry reports favorable safety profiles and functional outcomes. Future improvements should focus on workflow optimization and expanded data collection&#8212;including 90-day mRS scores and inflammatory markers&#8212;to enhance the registry&#8217;s dual role in quality improvement and hypothesis-driven research. Streamlining emergency responses, establishing early rehabilitation protocols, and developing cost-effective prognostic tools could significantly improve stroke outcomes in similar resource-limited settings.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors would like to thank the kind contribution of stroke center staff affiliated with the Tehran University of Medical Sciences.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Z.A. contributed to writing the original draft, methodology, statistical analysis, and editing. I.K. was involved in writing, as well as review and editing. S.H. contributed to data collection, imaging interpretation, and data validation. S.E. participated in methodology, data curation, and revision of the final manuscript. M.J. contributed to methodology and data collection. M.G. provided supervision and conceptualization. N.I. contributed to methodology, data analysis, and manuscript revision.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This study was funded by research deputy of Tehran University of Medical Sciences. The study&#8217;s design, data collection and analysis, publication choice, and article preparation were all done independently of the funding source.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The data that support the findings of this study are available from the corresponding author upon reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par53">The registry adheres to the ethical principles outlined in the Declaration of Helsinki. Ethical approval was obtained from the institutional review boards of all participating centers [IR.TUMS.MEDICINE.REC.1400.625].</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par54">Written informed consent was obtained from the patient.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par55">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Bill F, Foundation MG. Articles global, regional, and National burden of stroke and its risk factors, 1990&#8211;2021: a systematic analysis for the global burden of disease study 2021. 2024:973&#8211;1003. 10.1016/S1474-4422(24)00369-7.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(24)00369-7</pub-id><pub-id pub-id-type="pmcid">PMC12254192</pub-id><pub-id pub-id-type="pmid">39304265</pub-id></mixed-citation></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mendis</surname><given-names>S</given-names></name></person-group><article-title>Prevention and care of stroke in low- and middle-income countries; the need for a public health perspective</article-title><source>Int J Stroke</source><year>2010</year><volume>5</volume><fpage>86</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1111/j.1747-4949.2010.00406.x</pub-id><pub-id pub-id-type="pmid">20446942</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Mendis S. Prevention and care of stroke in low- and middle-income countries; the need for a public health perspective. Int J Stroke. 2010;5:86&#8211;91. 10.1111/j.1747-4949.2010.00406.x.<pub-id pub-id-type="pmid">20446942</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1747-4949.2010.00406.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saceleanu</surname><given-names>VM</given-names></name><name name-style="western"><surname>Toader</surname><given-names>C</given-names></name><name name-style="western"><surname>Ples</surname><given-names>H</given-names></name><name name-style="western"><surname>Covache-Busuioc</surname><given-names>RA</given-names></name><name name-style="western"><surname>Costin</surname><given-names>HP</given-names></name><name name-style="western"><surname>Bratu</surname><given-names>BG</given-names></name><etal/></person-group><article-title>Integrative approaches in acute ischemic stroke: from symptom recognition to future innovations</article-title><source>Biomedicines</source><year>2023</year><volume>11</volume><fpage>1</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.3390/biomedicines11102617</pub-id><pub-id pub-id-type="pmcid">PMC10604797</pub-id><pub-id pub-id-type="pmid">37892991</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Saceleanu VM, Toader C, Ples H, Covache-Busuioc RA, Costin HP, Bratu BG, et al. Integrative approaches in acute ischemic stroke: from symptom recognition to future innovations. Biomedicines. 2023;11:1&#8211;59. 10.3390/biomedicines11102617.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biomedicines11102617</pub-id><pub-id pub-id-type="pmcid">PMC10604797</pub-id><pub-id pub-id-type="pmid">37892991</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><collab>MICHA R. &#20083;&#40736;&#24515;&#32908;&#25552;&#21462; HHS Public Access</collab></person-group><source>Physiol Behav</source><year>2017</year><volume>176</volume><fpage>100</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1177/0022146515594631.Marriage</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">MICHA R. &#20083;&#40736;&#24515;&#32908;&#25552;&#21462; HHS Public Access. Physiol Behav. 2017;176:100&#8211;6. 10.1177/0022146515594631.Marriage.</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qurat Ul Ain</surname><given-names>H</given-names></name><name name-style="western"><surname>Junaid Tahir</surname><given-names>M</given-names></name><name name-style="western"><surname>Abbasher Hussien Mohamed Ahmed</surname><given-names>K</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>F</given-names></name><name name-style="western"><surname>Mohamed Ibrahim Ali</surname><given-names>M</given-names></name><name name-style="western"><surname>Hassan Salih Elhaj</surname><given-names>E</given-names></name><etal/></person-group><article-title>Tele-stroke: a strategy to improve acute stroke care in low- and middle-income countries</article-title><source>Ann Med Surg</source><year>2024</year><volume>86</volume><fpage>3808</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1097/ms9.0000000000002187</pub-id><pub-id pub-id-type="pmcid">PMC11230807</pub-id><pub-id pub-id-type="pmid">38989217</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Qurat Ul Ain H, Junaid Tahir M, Abbasher Hussien Mohamed Ahmed K, Ahmed F, Mohamed Ibrahim Ali M, Hassan Salih Elhaj E, et al. Tele-stroke: a strategy to improve acute stroke care in low- and middle-income countries. Ann Med Surg. 2024;86:3808&#8211;11. 10.1097/ms9.0000000000002187.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MS9.0000000000002187</pub-id><pub-id pub-id-type="pmcid">PMC11230807</pub-id><pub-id pub-id-type="pmid">38989217</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>Z</given-names></name><name name-style="western"><surname>Tang</surname><given-names>X</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y</given-names></name><name name-style="western"><surname>George</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Charness</surname><given-names>N</given-names></name><etal/></person-group><article-title>Clinical trial generalizability assessment in the big data era: A review</article-title><source>Clin Transl Sci</source><year>2020</year><volume>13</volume><fpage>675</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1111/cts.12764</pub-id><pub-id pub-id-type="pmid">32058639</pub-id><pub-id pub-id-type="pmcid">PMC7359942</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">He Z, Tang X, Yang X, Guo Y, George TJ, Charness N, et al. Clinical trial generalizability assessment in the big data era: A review. Clin Transl Sci. 2020;13:675&#8211;84. 10.1111/cts.12764.<pub-id pub-id-type="pmid">32058639</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cts.12764</pub-id><pub-id pub-id-type="pmcid">PMC7359942</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">Farhoudi M. Iranian stroke model-how to involve health policymakers Iranian stroke model-how to involve health. 2022;17.</mixed-citation></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alijanpour</surname><given-names>S</given-names></name><name name-style="western"><surname>Bahramnezhad</surname><given-names>F</given-names></name><name name-style="western"><surname>Mowla</surname><given-names>A</given-names></name><name name-style="western"><surname>Sabet</surname><given-names>MS</given-names></name><name name-style="western"><surname>Dehghan</surname><given-names>N</given-names></name></person-group><article-title>Updated protocol for stroke code management in prehospital settings: the Iranian comprehensive stroke code management program (ICSCM phase II) gency specialist</article-title><source>Working Group</source><year>2025</year><volume>13</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.22037/aaemj.v13i1.2633</pub-id><pub-id pub-id-type="pmcid">PMC12145130</pub-id><pub-id pub-id-type="pmid">40487908</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Alijanpour S, Bahramnezhad F, Mowla A, Sabet MS, Dehghan N. Updated protocol for stroke code management in prehospital settings: the Iranian comprehensive stroke code management program (ICSCM phase II) gency specialist. Working Group. 2025;13:1&#8211;16.<pub-id pub-id-type="doi" assigning-authority="pmc">10.22037/aaemj.v13i1.2633</pub-id><pub-id pub-id-type="pmcid">PMC12145130</pub-id><pub-id pub-id-type="pmid">40487908</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ung</surname><given-names>D</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J</given-names></name><name name-style="western"><surname>Thrift</surname><given-names>AG</given-names></name><name name-style="western"><surname>Cadilhac</surname><given-names>DA</given-names></name><name name-style="western"><surname>Andrew</surname><given-names>NE</given-names></name><name name-style="western"><surname>Sundararajan</surname><given-names>V</given-names></name><etal/></person-group><article-title>Promising use of big data to increase the efficiency and comprehensiveness of stroke outcomes research</article-title><source>Stroke</source><year>2019</year><volume>50</volume><fpage>1302</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1161/STROKEAHA.118.020372</pub-id><pub-id pub-id-type="pmid">31009352</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Ung D, Kim J, Thrift AG, Cadilhac DA, Andrew NE, Sundararajan V, et al. Promising use of big data to increase the efficiency and comprehensiveness of stroke outcomes research. Stroke. 2019;50:1302&#8211;9. 10.1161/STROKEAHA.118.020372.<pub-id pub-id-type="pmid">31009352</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STROKEAHA.118.020372</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cadilhac</surname><given-names>DA</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J</given-names></name><name name-style="western"><surname>Lannin</surname><given-names>NA</given-names></name><name name-style="western"><surname>Kapral</surname><given-names>MK</given-names></name><name name-style="western"><surname>Schwamm</surname><given-names>LH</given-names></name><name name-style="western"><surname>Dennis</surname><given-names>MS</given-names></name><etal/></person-group><article-title>National stroke registries for monitoring and improving the quality of hospital care: A systematic review</article-title><source>Int J Stroke</source><year>2016</year><volume>11</volume><fpage>28</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1177/1747493015607523</pub-id><pub-id pub-id-type="pmid">26763018</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Cadilhac DA, Kim J, Lannin NA, Kapral MK, Schwamm LH, Dennis MS, et al. National stroke registries for monitoring and improving the quality of hospital care: A systematic review. Int J Stroke. 2016;11:28&#8211;40. 10.1177/1747493015607523.<pub-id pub-id-type="pmid">26763018</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1747493015607523</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Powers</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Rabinstein</surname><given-names>AA</given-names></name><name name-style="western"><surname>Ackerson</surname><given-names>T</given-names></name><name name-style="western"><surname>Adeoye</surname><given-names>OM</given-names></name><name name-style="western"><surname>Bambakidis</surname><given-names>NC</given-names></name><name name-style="western"><surname>Becker</surname><given-names>K</given-names></name><etal/></person-group><article-title>Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American heart association/american stroke</article-title><source>Stroke</source><year>2019</year><volume>50</volume><fpage>e344</fpage><lpage>418</lpage><pub-id pub-id-type="pmid">31662037</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STR.0000000000000211</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American heart association/american stroke. Stroke. 2019;50:e344&#8211;418.<pub-id pub-id-type="pmid">31662037</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STR.0000000000000211</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">Methodology DC. RES-Q ( Registry of Stroke Care Quality) Data Collection Methodology 3 . 0 Standard Data; 2023.</mixed-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Liu L, Ding J, Leng X, Pu Y, Huang L, Xu A, et al. Guidelines for evaluation and management of cerebral collateral circulation in ischaemic stroke 2017. 2018. 10.1136/svn-2017-000135.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/svn-2017-000135</pub-id><pub-id pub-id-type="pmcid">PMC6169613</pub-id><pub-id pub-id-type="pmid">30294467</pub-id></mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">Beume L, Hieber M, Kaller CP, Nitschke K, Bardutzky J, Urbach H, et al. Large vessel occlusion acute stroke. 2018:2323&#8211;9. 10.1161/STROKEAHA.118.022253.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STROKEAHA.118.022253</pub-id><pub-id pub-id-type="pmid">30355088</pub-id></mixed-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="other">Lin Y-H, Liu M. Update on cerebral hyperperfusion syndrome. 2020;3:788&#8211;93. 10.1136/neurintsurg-2019-015621.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/neurintsurg-2019-015621</pub-id><pub-id pub-id-type="pmcid">PMC7402457</pub-id><pub-id pub-id-type="pmid">32414892</pub-id></mixed-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="other">Neuberger U, M&#246;hlenbruch MA, Herweh C, Ulfert C, Bendszus M, Pfaff J. Classification of bleeding events. 2017:1983&#8211;5. 10.1161/STROKEAHA.117.016735.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STROKEAHA.117.016735</pub-id><pub-id pub-id-type="pmid">28455322</pub-id></mixed-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">Mazya MV, Ahmed N, Ford GA, Hobohm C, Mikulik R, Nunes AP. Remote or extraischemic intracerebral hemorrhage &#8212; An uncommon complication of stroke thrombolysis. 2014:1657&#8211;63. 10.1161/STROKEAHA.114.004923.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STROKEAHA.114.004923</pub-id><pub-id pub-id-type="pmid">24788971</pub-id></mixed-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">Press D. Complications of the endovascular management of acute ischemic stroke. 2014:675&#8211;81.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/VHRM.S44349</pub-id><pub-id pub-id-type="pmcid">PMC4259256</pub-id><pub-id pub-id-type="pmid">25506222</pub-id></mixed-citation></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rukn</surname><given-names>SA</given-names></name><name name-style="western"><surname>Mazya</surname><given-names>MV</given-names></name><name name-style="western"><surname>Hentati</surname><given-names>F</given-names></name><name name-style="western"><surname>Sassi</surname><given-names>SB</given-names></name><name name-style="western"><surname>Nabli</surname><given-names>F</given-names></name><name name-style="western"><surname>Said</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Stroke in the Middle-East and North africa: A 2-year prospective observational study of stroke characteristics in the region-Results from the safe implementation of treatments in stroke (SITS)-Middle-East and North African (MENA)</article-title><source>Int J Stroke</source><year>2019</year><volume>14</volume><fpage>715</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1177/1747493019830331</pub-id><pub-id pub-id-type="pmid">30860454</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Rukn SA, Mazya MV, Hentati F, Sassi SB, Nabli F, Said Z, et al. Stroke in the Middle-East and North africa: A 2-year prospective observational study of stroke characteristics in the region-Results from the safe implementation of treatments in stroke (SITS)-Middle-East and North African (MENA). Int J Stroke. 2019;14:715&#8211;22. 10.1177/1747493019830331.<pub-id pub-id-type="pmid">30860454</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1747493019830331</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wafa</surname><given-names>HA</given-names></name><name name-style="western"><surname>Wolfe</surname><given-names>CDA</given-names></name><name name-style="western"><surname>Emmett</surname><given-names>E</given-names></name><name name-style="western"><surname>Roth</surname><given-names>GA</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>CO</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>Burden of stroke in europe: thirty-year projections of incidence, prevalence, deaths, and disability-adjusted life years</article-title><source>Stroke</source><year>2020</year><volume>51</volume><fpage>2418</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">32646325</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STROKEAHA.120.029606</pub-id><pub-id pub-id-type="pmcid">PMC7382540</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Wafa HA, Wolfe CDA, Emmett E, Roth GA, Johnson CO, Wang Y. Burden of stroke in europe: thirty-year projections of incidence, prevalence, deaths, and disability-adjusted life years. Stroke. 2020;51:2418&#8211;27.<pub-id pub-id-type="pmid">32646325</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STROKEAHA.120.029606</pub-id><pub-id pub-id-type="pmcid">PMC7382540</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="other">Ahmed N, Hermansson K, Bluhmki E, Danays T, Nunes AP, Kenton A et al. The SITS-UTMOST: a registry-based prospective study in Europe investigating the impact of regulatory approval of intravenous Actilyse in the extended time window (3&#8211;4. 5&#160;h) in acute ischaemic stroke. 2016;1:213&#8211;21. 10.1177/2396987316661890.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/2396987316661890</pub-id><pub-id pub-id-type="pmcid">PMC6301239</pub-id><pub-id pub-id-type="pmid">31008282</pub-id></mixed-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Aziz ZA, Lee YYL, Ngah BA, Sidek NN, Looi I, Hanip R, et al. Acute stroke registry malaysia, 2010&#8211;2014 : results from the National neurology registry. J Stroke Cerebrovasc Dis. 2015:2010&#8211;4. 10.1016/j.jstrokecerebrovasdis.2015.07.025.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jstrokecerebrovasdis.2015.07.025</pub-id><pub-id pub-id-type="pmid">26338106</pub-id></mixed-citation></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gabet</surname><given-names>A</given-names></name><name name-style="western"><surname>Guenancia</surname><given-names>C</given-names></name><name name-style="western"><surname>Duloquin</surname><given-names>G</given-names></name><name name-style="western"><surname>Oli&#233;</surname><given-names>V</given-names></name><name name-style="western"><surname>B&#233;jot</surname><given-names>Y</given-names></name></person-group><article-title>Ischemic stroke with atrial fibrillation: characteristics and time trends 2006 to 2017 in the Dijon stroke registry</article-title><source>Stroke</source><year>2021</year><volume>52</volume><fpage>2077</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1161/strokeaha.120.030812</pub-id><pub-id pub-id-type="pmid">33874745</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Gabet A, Guenancia C, Duloquin G, Oli&#233; V, B&#233;jot Y. Ischemic stroke with atrial fibrillation: characteristics and time trends 2006 to 2017 in the Dijon stroke registry. Stroke. 2021;52:2077&#8211;85. 10.1161/strokeaha.120.030812.<pub-id pub-id-type="pmid">33874745</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STROKEAHA.120.030812</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barnes</surname><given-names>GD</given-names></name><name name-style="western"><surname>Piazza</surname><given-names>G</given-names></name></person-group><article-title>Barriers to stroke prevention in atrial fibrillation: insights from the global anticoagulation roundtable</article-title><source>Int J Cardiol Hear Vasc</source><year>2022</year><volume>42</volume><fpage>101096</fpage><pub-id pub-id-type="doi">10.1016/j.ijcha.2022.101096</pub-id><pub-id pub-id-type="pmcid">PMC9356154</pub-id><pub-id pub-id-type="pmid">35942005</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Barnes GD, Piazza G. Barriers to stroke prevention in atrial fibrillation: insights from the global anticoagulation roundtable. Int J Cardiol Hear Vasc. 2022;42:101096. 10.1016/j.ijcha.2022.101096.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijcha.2022.101096</pub-id><pub-id pub-id-type="pmcid">PMC9356154</pub-id><pub-id pub-id-type="pmid">35942005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">Karlinski AVDJMA, Gdovinova Z, Mikulik JKGTR. Clinical outcome of cardioembolic stroke treated by intravenous thrombolysis. 2017:1&#8211;9 . 10.1111/ane.12880.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ane.12880</pub-id><pub-id pub-id-type="pmid">29218699</pub-id></mixed-citation></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="other">Kim DY, Park TH, Cho Y, Park J, Lee K, Lee M, et al. Contemporary statistics of acute ischemic stroke and transient ischemic attack in 2021: insights from the CRCS-K-NIH registry. 2024;39:1&#8211;26.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3346/jkms.2024.39.e278</pub-id><pub-id pub-id-type="pmcid">PMC11372415</pub-id><pub-id pub-id-type="pmid">39228188</pub-id></mixed-citation></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ornello</surname><given-names>R</given-names></name><name name-style="western"><surname>Degan</surname><given-names>D</given-names></name><name name-style="western"><surname>Tiseo</surname><given-names>C</given-names></name><name name-style="western"><surname>Di Carmine</surname><given-names>C</given-names></name><name name-style="western"><surname>Perciballi</surname><given-names>L</given-names></name><name name-style="western"><surname>Pistoia</surname><given-names>F</given-names></name><etal/></person-group><article-title>Distribution and Temporal trends from 1993 to 2015 of ischemic stroke subtypes: A systematic review and Meta-Analysis</article-title><source>Stroke</source><year>2018</year><volume>49</volume><fpage>814</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1161/strokeaha.117.020031</pub-id><pub-id pub-id-type="pmid">29535272</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Ornello R, Degan D, Tiseo C, Di Carmine C, Perciballi L, Pistoia F, et al. Distribution and Temporal trends from 1993 to 2015 of ischemic stroke subtypes: A systematic review and Meta-Analysis. Stroke. 2018;49:814&#8211;9. 10.1161/strokeaha.117.020031.<pub-id pub-id-type="pmid">29535272</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STROKEAHA.117.020031</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="other">Sch&#246;berl F, Ringleb PA, Wakili R, Poli S, Wollenweber FA, Kellert L. Juvenile Stroke 2017. 10.3238/arztebl.2017.0527.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3238/arztebl.2017.0527</pub-id><pub-id pub-id-type="pmcid">PMC5624273</pub-id><pub-id pub-id-type="pmid">28835326</pub-id></mixed-citation></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barow</surname><given-names>E</given-names></name><name name-style="western"><surname>Boutitie</surname><given-names>F</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>B</given-names></name><name name-style="western"><surname>Cho</surname><given-names>TH</given-names></name><name name-style="western"><surname>Ebinger</surname><given-names>M</given-names></name><name name-style="western"><surname>Endres</surname><given-names>M</given-names></name><etal/></person-group><article-title>Functional outcome of intravenous thrombolysis in patients with lacunar infarcts in the WAKE-UP trial</article-title><source>JAMA Neurol</source><year>2019</year><volume>76</volume><fpage>641</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2019.0351</pub-id><pub-id pub-id-type="pmid">30907934</pub-id><pub-id pub-id-type="pmcid">PMC6563546</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Barow E, Boutitie F, Cheng B, Cho TH, Ebinger M, Endres M, et al. Functional outcome of intravenous thrombolysis in patients with lacunar infarcts in the WAKE-UP trial. JAMA Neurol. 2019;76:641&#8211;9. 10.1001/jamaneurol.2019.0351.<pub-id pub-id-type="pmid">30907934</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2019.0351</pub-id><pub-id pub-id-type="pmcid">PMC6563546</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saver</surname><given-names>JL</given-names></name></person-group><article-title>Time is brain&#8212;quantified</article-title><source>Stroke</source><year>2006</year><volume>37</volume><fpage>263</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">16339467</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/01.STR.0000196957.55928.ab</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Saver JL. Time is brain&#8212;quantified. Stroke. 2006;37:263&#8211;6.<pub-id pub-id-type="pmid">16339467</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/01.STR.0000196957.55928.ab</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jauch</surname><given-names>EC</given-names></name><name name-style="western"><surname>Saver</surname><given-names>JL</given-names></name><name name-style="western"><surname>Adams</surname><given-names>HP</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Bruno</surname><given-names>A</given-names></name><name name-style="western"><surname>Connors</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Demaerschalk</surname><given-names>BM</given-names></name><etal/></person-group><article-title>Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American heart association/american stroke association</article-title><source>Stroke</source><year>2013</year><volume>44</volume><fpage>870</fpage><lpage>947</lpage><pub-id pub-id-type="pmid">23370205</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STR.0b013e318284056a</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American heart association/american stroke association. Stroke. 2013;44:870&#8211;947.<pub-id pub-id-type="pmid">23370205</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STR.0b013e318284056a</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamal</surname><given-names>N</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>S</given-names></name><name name-style="western"><surname>Xian</surname><given-names>Y</given-names></name><name name-style="western"><surname>Matsouaka</surname><given-names>R</given-names></name><name name-style="western"><surname>Hill</surname><given-names>MD</given-names></name><name name-style="western"><surname>Bhatt</surname><given-names>DL</given-names></name><etal/></person-group><article-title>Delays in door-to-needle times and their impact on treatment time and outcomes in get with the guidelines-stroke</article-title><source>Stroke</source><year>2017</year><volume>48</volume><fpage>946</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">28228574</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STROKEAHA.116.015712</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Kamal N, Sheng S, Xian Y, Matsouaka R, Hill MD, Bhatt DL, et al. Delays in door-to-needle times and their impact on treatment time and outcomes in get with the guidelines-stroke. Stroke. 2017;48:946&#8211;54.<pub-id pub-id-type="pmid">28228574</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STROKEAHA.116.015712</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yaghi</surname><given-names>S</given-names></name><name name-style="western"><surname>Eisenberger</surname><given-names>A</given-names></name><name name-style="western"><surname>Willey</surname><given-names>JZ</given-names></name></person-group><article-title>Symptomatic intracerebral hemorrhage in acute ischemic stroke after thrombolysis with intravenous Recombinant tissue plasminogen activator: a review of natural history and treatment</article-title><source>JAMA Neurol</source><year>2014</year><volume>71</volume><fpage>1181</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2014.1210</pub-id><pub-id pub-id-type="pmid">25069522</pub-id><pub-id pub-id-type="pmcid">PMC4592535</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Yaghi S, Eisenberger A, Willey JZ. Symptomatic intracerebral hemorrhage in acute ischemic stroke after thrombolysis with intravenous Recombinant tissue plasminogen activator: a review of natural history and treatment. JAMA Neurol. 2014;71:1181&#8211;5. 10.1001/jamaneurol.2014.1210.<pub-id pub-id-type="pmid">25069522</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaneurol.2014.1210</pub-id><pub-id pub-id-type="pmcid">PMC4592535</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raquin</surname><given-names>M</given-names></name><name name-style="western"><surname>Lambert</surname><given-names>C</given-names></name><name name-style="western"><surname>Paris</surname><given-names>P</given-names></name><name name-style="western"><surname>Bourgois</surname><given-names>N</given-names></name><name name-style="western"><surname>Clavelou</surname><given-names>P</given-names></name><name name-style="western"><surname>Moisset</surname><given-names>X</given-names></name><etal/></person-group><article-title>Original Article mothership versus Drip-and-Ship for stroke in a rural area: A French prospective observational study</article-title><source>Rev Neurol (Paris)</source><year>2024</year><volume>181</volume><fpage>67</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/j.neurol.2024.06.007</pub-id><pub-id pub-id-type="pmid">39079883</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Raquin M, Lambert C, Paris P, Bourgois N, Clavelou P, Moisset X, et al. Original Article mothership versus Drip-and-Ship for stroke in a rural area: A French prospective observational study. Rev Neurol (Paris). 2024;181:67&#8211;78. 10.1016/j.neurol.2024.06.007.<pub-id pub-id-type="pmid">39079883</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neurol.2024.06.007</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="other">Thrombectomy SMAM. Mechanical thrombectomy global access for. 2023:1208&#8211;20. 10.1161/CIRCULATIONAHA.122.063366.</mixed-citation></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="other">Aroor SR, Asif KS, Potter-vig J, Sharma A, Menon BK, Inoa V. Mechanical thrombectomy access for all ? Challenges in increasing endovascular treatment for acute ischemic stroke in the United States. J Stroke. 2022;24:41&#8211;8.<pub-id pub-id-type="doi" assigning-authority="pmc">10.5853/jos.2021.03909</pub-id><pub-id pub-id-type="pmcid">PMC8829477</pub-id><pub-id pub-id-type="pmid">35135058</pub-id></mixed-citation></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnston</surname><given-names>SC</given-names></name><name name-style="western"><surname>Amarenco</surname><given-names>P</given-names></name><name name-style="western"><surname>Denison</surname><given-names>H</given-names></name><name name-style="western"><surname>Evans</surname><given-names>SR</given-names></name><name name-style="western"><surname>Himmelmann</surname><given-names>A</given-names></name><name name-style="western"><surname>James</surname><given-names>S</given-names></name><etal/></person-group><article-title>Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA</article-title><source>N Engl J Med</source><year>2020</year><volume>383</volume><fpage>207</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">32668111</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1916870</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Johnston SC, Amarenco P, Denison H, Evans SR, Himmelmann A, James S, et al. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N Engl J Med. 2020;383:207&#8211;17.<pub-id pub-id-type="pmid">32668111</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1916870</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amarenco</surname><given-names>P</given-names></name><name name-style="western"><surname>Benavente</surname><given-names>O</given-names></name><name name-style="western"><surname>Goldstein</surname><given-names>LB</given-names></name><name name-style="western"><surname>Callahan</surname><given-names>A</given-names><suffix>III</suffix></name><name name-style="western"><surname>Sillesen</surname><given-names>H</given-names></name><name name-style="western"><surname>Hennerici</surname><given-names>MG</given-names></name><etal/></person-group><article-title>Results of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial by stroke subtypes</article-title><source>Stroke</source><year>2009</year><volume>40</volume><fpage>1405</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">19228842</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STROKEAHA.108.534107</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Amarenco P, Benavente O, Goldstein LB, Callahan A III, Sillesen H, Hennerici MG, et al. Results of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) trial by stroke subtypes. Stroke. 2009;40:1405&#8211;9.<pub-id pub-id-type="pmid">19228842</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STROKEAHA.108.534107</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>N&#237; Chr&#243;in&#237;n</surname><given-names>D</given-names></name><name name-style="western"><surname>Asplund</surname><given-names>K</given-names></name><name name-style="western"><surname>&#197;sberg</surname><given-names>S</given-names></name><name name-style="western"><surname>Callaly</surname><given-names>E</given-names></name><name name-style="western"><surname>Cuadrado-Godia</surname><given-names>E</given-names></name><name name-style="western"><surname>D&#237;ez-Tejedor</surname><given-names>E</given-names></name><etal/></person-group><article-title>Statin therapy and outcome after ischemic stroke: systematic review and meta-analysis of observational studies and randomized trials</article-title><source>Stroke</source><year>2013</year><volume>44</volume><fpage>448</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">23287777</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STROKEAHA.112.668277</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">N&#237; Chr&#243;in&#237;n D, Asplund K, &#197;sberg S, Callaly E, Cuadrado-Godia E, D&#237;ez-Tejedor E, et al. Statin therapy and outcome after ischemic stroke: systematic review and meta-analysis of observational studies and randomized trials. Stroke. 2013;44:448&#8211;56.<pub-id pub-id-type="pmid">23287777</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/STROKEAHA.112.668277</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ogilvie</surname><given-names>BW</given-names></name><name name-style="western"><surname>Yerino</surname><given-names>P</given-names></name><name name-style="western"><surname>Kazmi</surname><given-names>F</given-names></name><name name-style="western"><surname>Buckley</surname><given-names>DB</given-names></name><name name-style="western"><surname>Rostami-Hodjegan</surname><given-names>A</given-names></name><name name-style="western"><surname>Paris</surname><given-names>BL</given-names></name><etal/></person-group><article-title>The proton pump inhibitor, omeprazole, but not Lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel</article-title><source>Drug Metab Dispos</source><year>2011</year><volume>39</volume><fpage>2020</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">21795468</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.111.041293</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Ogilvie BW, Yerino P, Kazmi F, Buckley DB, Rostami-Hodjegan A, Paris BL, et al. The proton pump inhibitor, omeprazole, but not Lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel. Drug Metab Dispos. 2011;39:2020&#8211;33.<pub-id pub-id-type="pmid">21795468</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.111.041293</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Collaboration</surname><given-names>CT</given-names></name></person-group><article-title>Effectiveness of intermittent pneumatic compression in reduction of risk of deep vein thrombosis in patients who have had a stroke (CLOTS 3): a multicentre randomised controlled trial</article-title><source>Lancet</source><year>2013</year><volume>382</volume><fpage>516</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">23727163</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(13)61050-8</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Collaboration CT. Effectiveness of intermittent pneumatic compression in reduction of risk of deep vein thrombosis in patients who have had a stroke (CLOTS 3): a multicentre randomised controlled trial. Lancet. 2013;382:516&#8211;24.<pub-id pub-id-type="pmid">23727163</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(13)61050-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benfield</surname><given-names>JK</given-names></name><name name-style="western"><surname>Everton</surname><given-names>LF</given-names></name><name name-style="western"><surname>Bath</surname><given-names>PM</given-names></name><name name-style="western"><surname>England</surname><given-names>TJ</given-names></name></person-group><article-title>Accuracy and clinical utility of comprehensive dysphagia screening assessments in acute stroke: A systematic review and meta-analysis</article-title><source>J Clin Nurs</source><year>2020</year><volume>29</volume><fpage>1527</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">31970825</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jocn.15192</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Benfield JK, Everton LF, Bath PM, England TJ. Accuracy and clinical utility of comprehensive dysphagia screening assessments in acute stroke: A systematic review and meta-analysis. J Clin Nurs. 2020;29:1527&#8211;38.<pub-id pub-id-type="pmid">31970825</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jocn.15192</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanna</surname><given-names>T</given-names></name><name name-style="western"><surname>Diener</surname><given-names>H-C</given-names></name><name name-style="western"><surname>Passman</surname><given-names>RS</given-names></name><name name-style="western"><surname>Di Lazzaro</surname><given-names>V</given-names></name><name name-style="western"><surname>Bernstein</surname><given-names>RA</given-names></name><name name-style="western"><surname>Morillo</surname><given-names>CA</given-names></name><etal/></person-group><article-title>Cryptogenic stroke and underlying atrial fibrillation</article-title><source>N Engl J Med</source><year>2014</year><volume>370</volume><fpage>2478</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">24963567</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1313600</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Sanna T, Diener H-C, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014;370:2478&#8211;86.<pub-id pub-id-type="pmid">24963567</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1313600</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>